RE:NEWS OUTUsually, I support the decisions that PL takes. But this time, I am not sure it's a good one. I did a few research on the past of Mr Weaver:
PROMETIC : nov 2015 to ?
ORYZON GENOMICS : jan 2015 to nov 2015
FIBROCELL SCIENCE : sept 2013 to jan 2015
CELSION. : july 2011 to sept 2013
Prior to Celsion, Weaver served as CFO for six other biotechnology companies, including Poniard Pharmaceuticals, Talyst, Inc., Sirna Therapeutics, Nastech Pharmaceutical Co., Ilex Oncology and Prism Technologies and consulted for countless others. Over the course of his career, he has managed corporate and situation-specific financing strategies, dramatically increased multiple market cap valuations and overseen multiple product and service revenue channels, and manufacturing supply relationships.
He constantly change of job and the stock price has dropped when he was CFO of Fibrocell (sept 2013: ~4 $ jan 2015 ~3.5 $) and Celsion (july 2011: ~14 $ sept 2013 ~5 $). Oryzon is a private company, so unable to see any chart. I didn't look further.
Hope I am wrong in my personnal thinking !
GLTA longs,
FrancoQc